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There is a critical need for appropriate technical innovation and
development, as well as dramatically improved health sector
financing
I
n recent years the case for antiretroviral
therapy (ART) in those countries hard-
est hit by the HIV pandemic is seldom
contested. Prior to the widespread avail-
ability of antiretroviral therapy in many
developing countries, there were however
frequent concerns expressed about the
safety and feasibility of promoting wide-
spread access to ART in countries such as
those in Southern Africa. These concerns
were premised on the potential ‘‘anarchy’’
that might be the result of weak health
systems leading to widespread virological
resistance,1 2 on the grounds that there
were more cost-effective interventions
available given the limited funding bas-
kets at the time,3 and on the potential to
do more harm than good if introducing
large and complex new interventions into
already weak and fragmented health
systems, further increasing inequities.4 5
The first public-sector ART treatment
programmes in developing countries
(with the exception of Brazil) date back
to 2000,6 and data are now emerging on
the effectiveness of the interventions.
SURVIVAL IN TREATMENT
PROGRAMMES IN DEVELOPING
COUNTRIES
Three clear messages are emerging from
the accumulating outcomes reporting
from public-sector adult ART treatment
programmes in poor countries. First,
treatment is effective for those accessing
ART. Hogan summarised eight pro-
grammes from resource-limited settings,7
demonstrating a range of survival out-
comes at 1 and 2 years on ART, but all
showing marked improvements over the
anticipated natural history without ART.
The comparative median survival in those
eligible but not receiving ART is variously
reported as 24 months, and less than a
year for CD4 counts of less than 200 and
less than 50 cells/ml, respectively.8
More recently the ART-LINC collabora-
tion demonstrated cumulative mortality
at 1 year of 6.4% in 2725 patients across
12 cohorts with active follow-up proce-
dures in place.9 The city-wide treatment
programme in Lusaka reported a mortal-
ity of 16.1/100 person years of ART while
rapidly scaling up care to over 16 000
patients.10 In Malawi, cross-sectionally
across 7000 adult patients who ever
started ART, 74% remained alive and in
care, while cumulatively 10% were esti-
mated to have died by 1 year.11 Mortality
estimates at longer durations on ART
include 16.9% of patients having died by
5 years in a cohort in South Africa,12 and
24.6% by 5 years in a cohort in Senegal.13
Second, in spite of this massive health
gain from the intervention, compared
with the richest countries, there is still a
higher mortality in the first 6 months of
treatment in developing countries. The
ART-LINC study referred to above
demonstrated that compared with the
ART-CC cohort collaboration from
Europe and North America, patients
starting ART in developing countries were
at up to 4 times greater risk of dying in
the first few months on ART after
controlling for available measures of
disease advancement at baseline. This
corroborates the experience of many
individual developing country cohorts
who describe around two-thirds of all
deaths on ART occurring in the first few
months of treatment.14 15 It is probable
that the burden of co-morbidities could
contribute to the early mortality as
evidenced by autopsy studies which
show frequent undiagnosed tuberculosis
and other bacterial infections.16 Due to
the extreme differences in access to
healthcare, it may also be that clinically
there are residual differences across
regions between patients in the same
CD4 count and clinical stage strata.
Third, the evaluation of programme
effectiveness is hindered by the patients
who are lost to programmes—given the
limited resources available, there is a fine
balance between enrolling as many
patients as possible, and retaining those
already in care. The proportion of patients
lost to care at various durations of follow-
up often approaches or exceeds the propor-
tion known to have died. Even programmes
who attempt to actively trace patients who
are lost to follow-up, may end up under-
reporting the number of deaths. One study
of patients lost to follow-up in Malawi
demonstrated that half the patients who
had been lost had died, and of those, 58%
had died in the 3 months following their
last clinic visit.17 After 5 years of follow-up
in Khayelitsha, the proportion lost to care
increased from the 16.9% known to have
died to 20.3% or 28.2% depending on
whether 365 or 90 days were used as the
definition of loss to follow-up.12
POPULATION-LEVEL IMPACT
Although on-programme ART effective-
ness, even in some of the most challen-
ging settings, has been shown to be good,
it is important to reflect on whether or
not treatment is being provided at suffi-
cient scale to impact on the greatly
reduced life expectancy in heavily
affected countries. While global agencies
have set a goal of reaching universal
access to ART by 2010 (80% of those in
need of ART accessing it), it is well
documented that the majority of coun-
tries are falling well short of this tar-
get.12 18 Where systems enable pre-ART
mortality to be measured, a disconcerting
pattern is emerging whereby the majority
of on-programme deaths are occurring
prior to patients accessing ART.15 19
Reported ART programme outcomes
mask continued high HIV-related mortal-
ity among patients receiving some care
but not yet on ART. Even less visible are
the deaths among those unable to access
care at all: in many settings, issues such
as stigma, user fees, distance from ser-
vices and the non-availability of services
still contrive to prevent people from
accessing care in the first place.
There are few opportunities to truly
explore the impact of ART at a population
level. In Brazil where universal access to
ART has been available for longer,
researchers were able to demonstrate
temporal improvements in the survival
of patients with AIDS in representative
samples from different time periods.20
This has been accompanied by a docu-
mented decrease in hospital admissions.21
Earlier this year, researchers in South
Africa were able to demonstrate for the
first time that the previously inexorable
year-on-year increase in recorded death
rates through the vital registration system
had in some provinces slowed down, with
the age, gender and geographical profiles
of the gains being aligned with those of
the patient population accessing ART.22
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Even at moderate coverage, it appears the
survival benefits at a population level are
starting to be discernible.
A characteristic of treatment pro-
grammes in Southern Africa is the pre-
dominance of women among adults
accessing care whereby two-thirds of new
patients are women.23 This disproportion
could not be predicted by the epidemiology
of the epidemic alone, suggesting differ-
ential healthcare access between men and
women in this region. While children are
not discussed in detail here, the results of
ART in children in developing countries are
similarly encouraging.
ADHERENCE, VIROLOGICAL
SUPPRESSION AND RESISTANCE
Given that the majority of scaling up of
ART has occurred in the past few years,
differences in adherence between rich
and poor countries may not yet have
translated into medium or long-term
mortality differences. Ivers conducted a
meta-analysis of virological suppression
in the first year on ART, and found that in
10 predominantly African programmes,
proportions of patients suppressing their
viral load were similar to those from
richer countries, with a combined esti-
mate of virological suppression of 70% at
6 months and 57% at 1 year. Individual
programmes have however demonstrated
much higher proportions of patients with
virological suppression.24 25 Egger pre-
sented a comparison between these pro-
grammes and the Swiss HIV cohort,26 and
demonstrated that the time to virological
suppression and time to rebound were
comparable after adjusting for the fre-
quency of viral load measurements.
Given that the treatment populations in
these settings are largely ART-naı¨ve, and
are not necessarily marginalised commu-
nities, it is anticipated that virological
outcomes should be good in the early years
of scaling up, while access to the structured
treatment programmes and adherence
counselling remains good. The early con-
cerns about resistance resulted in pro-
gramme designs that were very
structured, and that placed a premium on
counselling and support. Adherence stu-
dies based largely on self-reports also
demonstrate that where access to care is
good (as in most research settings),
patients in sub-Saharan Africa take their
medications as reliably if not more reliably
than patients in North America.27
The poor availability of treatment in
developing countries prior to the scaling-
up initiatives has resulted in low levels of
transmitted resistance in patients starting
ART in these countries, obviating the
need for routine resistance testing in
patients starting ART.28 29 Genotypic stu-
dies of patients failing their first-line
regimens demonstrate however high-
level resistance to two out of three classes
of drug in most instances.30
Linked to the fear of emerging drug
resistance is the concern that the avail-
ability of treatment would lead to an
increase in unsafe sexual practices. A
review was unable to demonstrate any
evidence as yet of behavioural disinhibi-
tion as a result of ART availability in
developing countries,31 albeit that there
are as yet very few studies addressing this
question. Conventionally most commen-
tators have assumed that the availability
of treatment would rather strengthen
prevention interventions.32
CHALLENGES
Each year, the demand on the health
systems in the countries with the largest
HIV disease burden is greater than the
year before, and yet the systems them-
selves are buckling under the already
increased load of ART, with little capacity
for the impending burden of care that
must follow the further scaling up of
ART. In spite of all the innovation
associated with delivering ART through
primary care services, the intervention is
exposing inherent systemic weaknesses
in the health systems of many poor
countries. Earlier this year, Me´decins
Sans Frontie`res drew attention to the
health worker crisis in the face of the
HIV/AIDS challenges, focussing on
Malawi, Mozambique, Lesotho and
South Africa.33 In addition to trying to
cope with the immediate staff shortages
through retention interventions and task-
shifting, the report called for donors to
support recurrent human resource costs,
as well as for countries to spend more on
health overall and human resource devel-
opment in particular. In 2001, African
governments undertook to commit 15%
of annual budgets to healthcare in the
Abudja declaration. Countries are falling
well short of this stated goal.
It is an unfair expectation of health
services in many countries to expect that
they alone can enrol and retain huge
numbers of patients in care on such an
unprecedented scale. In addition to
improved financing of health services,
national responses at a political and civil
society level are key to ensuring that
maximal benefit is derived from the
health sector investments, as demon-
strated by contrasting HIV/AIDS policies
between Uganda and South Africa.34
BALANCING PROGRAMME
SOPHISTICATION AGAINST
COVERAGE
Senior health officials from Malawi wrote
an impassioned plea in the Lancet
requesting that the global treatment
community do not add complexity to
treatment guidelines, given the chal-
lenges that country was facing in meeting
their target of 50% coverage of ART.35 This
target could be threatened if pressure for
more complex monitoring and pervasive
access to second-line drugs was priori-
tised. This highlights the tension between
optimal clinical design and health service
factors that facilitate scaling up care. For
example, data are gradually becoming
more compelling in support of earlier
initiation of ART than the traditional
threshold of a CD4 count of 200 cells/ml
contained in many developing country
guidelines, while the health service con-
sequence of raising this threshold is an
even bigger treatment backlog.
The mainstay of treatment in Southern
Africa is based on a generic first-line
fixed-dose combination of stavudine,
lamivudine and nevirapine taken as a
single tablet twice daily. The appeal of an
affordable and standardised combination
such as this is obvious as stated by the
Malawi officials, and yet there are clinical
concerns. The regimen is poorly tolerated
by some individuals with an unfavourable
short- and long-term toxicity profile of
stavudine,36 37 and there are concerns
about concomitant use of nevirapine with
rifampicin-containing tuberculosis treat-
ment in a setting where up to a third of
patients starting ART have prevalent
tuberculosis. Better fixed-dose combina-
tions are available, but less affordable,
and some countries are in a position to
provide second-line regimens but are
limited by the high cost of alternative
regimens. The international trade envir-
onment continues to fail patients with
respect to ensuring the availability of
newer treatment to poor countries.38 39
The monitoring of treatment response
varies between immunological and viro-
logical in poor countries. The added value
of virological measures at a programme
level are debated, and guidelines for
resource-limited setting do not make
virological monitoring obligatory. On the
other hand, viral load measures are
potentially an invaluable tool for asses-
sing adherence, and innovations that
would allow point-of-care immunological
and virological monitoring are urgently
needed.40
More than ever there is a critical need for
technical innovation and development, but
with a view to treatment simplification and
ease of service delivery, as opposed to
adding complexity to existing treatment
guidelines. This means adapting the
research and development agenda to the
reality of resource-poor settings where
skilled staff are in short supply, health
services are spread all too thin, treatment
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must be provided at the most basic primary
care level, and need continues to far out-
strip the availability of services.
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Vaginal practices, microbicides and HIV:
what do we need to know?
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The goal of a safer vaginal environment could be reached by
identifying harmful vaginal practices and an effective microbicide,
thereby increasing options for HIV prevention
T
he global burden of HIV, its increas-
ing feminisation, and chronic diffi-
culties with development of options
for HIV prevention all argue for an
intensified re-examination of factors
influencing the efficiency of heterosexual
HIV transmission. This includes vaginal
practices and products used by large
numbers of women worldwide to tighten,
dry, warm and clean their vagina.
Women’s efforts to change their genital
environment can undermine each com-
ponent of innate defences against patho-
gens.1 In particular, vaginal practices have
been linked with loss of lactobacilli and
disruption of the vaginal epithelium.2–4
These practices may therefore be an
important mediator in acquisition of STI,
including HIV, or worsen pre-existing
infections. Despite this, surprisingly little
is known about the effects of specific
vaginal practices on HIV transmission
dynamics.
In past decades, both cross-sectional
and longitudinal studies have found an
association between intravaginal cleans-
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